Printer Friendly
The Free Library
14,800,529 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Zacks Analyst Blog Highlights: Playtex, Procter & Gamble, Johnson & Johnson and Cerus Corp.


CHICAGO -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Playtex Products (NYSE NYSE

See: New York Stock Exchange
: PYX pyx also pix  
n.
1. Ecclesiastical
a. A container in which wafers for the Eucharist are kept.

b. A container in which the Eucharist is carried to the sick.

2.
), Procter & Gamble (NYSE: PG), Johnson & Johnson (NYSE: JNJ JNJ Johnson and Johnson (stock symbol)
JNJ Journal of Nursing Jocularity
) and Cerus Corp. (Nasdaq: CERS).

See the latest posts to the Analyst Blog by visiting: http://at.zacks.com/?id=2673

Here are highlights from Tuesday's Analyst Blog:

Keep a Sell on Playtex

Management at Playtex Products (NYSE: PYX) is investing in new product innovations to enhance market share and top-line performance. However, Playtex competes against companies with large resources, such as Procter & Gamble (NYSE: PG) and Johnson & Johnson (NYSE: JNJ); hence, investments in marketing and a heavy debt burden restrain profit growth.

In February 2006, management reduced long-term growth targets for sales and operating income Operating Income

The profit realized from a business' own operations.

Notes:
This would not include income from things such as investments in other firms. Also referred to as operating profit or recurring profit.
. Despite the recent acquisition of a large position in Playtex by Harbert Management, the high valuation level compels us to maintain a Sell recommendation.

Cerus Upped from Sell

Given the current valuation, our rating on Cerus Corp. (Nasdaq: CERS) moves to Hold. The company received CE Mark approval for plasma and issued 3.9 million shares in an equity offering that alleviates financing concerns near-term. However, our 2007 estimates decline on lower R&D funding.

We believe the stock is fairly valued at 40x our 2010 EPS (Encapsulated PostScript) A PostScript file format used to transfer a graphic image between applications and platforms. EPS files contain PostScript code as well as an optional preview image in TIFF, WMF, PICT or EPSI, the latter being an ASCII-only format.  estimate of $0.59, discounted 40%. Our $6.00 target is equivalent to 7.4x 2007 revenues.

See the latest posts to the Analyst Blog by visiting http://at.zacks.com/?id=2645

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis Qualitative Analysis

Securities analysis that uses subjective judgment based on nonquantifiable information, such as management expertise, industry cycles, strength of research and development, and labor relations.
 to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to Verb 1. subscribe to - receive or obtain regularly; "We take the Times every day"
subscribe, take

buy, purchase - obtain by purchase; acquire by means of a financial transaction; "The family purchased a new car"; "The conglomerate acquired a new company";
 this free newsletter today by visiting http://at.zacks.com/?id=2674.

About Zacks

Zacks.com is a property of Zacks Investment Research Zacks Investment Research

A firm that compiles earnings estimates and brokerage firm investment recommendations for thousands of publicly traded firms.
, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform Outperform

An analyst recommendation meaning a stock is expected to do slightly better than the market return.

Notes:
Exact definitions vary by brokerage, but in general this rating is better than neutral and worse than buy or strong buy.
 the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 3, 2007
Words:492
Previous Article:Lexar Demonstrates 'Innovation from the Inside Out' at CES 2007.
Next Article:Ultimate Software to Present January 10th at Needham & Company's Ninth Annual Growth Conference.
Topics:



Related Articles
The value of market positioning: Anthony Epps selects companies poised to grow in the face of market uncertainty.(STOCK PICKS)
Zacks Analyst Blog Highlights: MedImmune, Inc., Mittal Steel, Cia Siderurgica Nacional, Cerus Corporation and Digital River.
Zacks Analyst Blog Highlights: Phelps Dodge, Inco, Falconbridge, Pfizer and Johnson & Johnson.
Zacks Analyst Blog Highlights: Johnson & Johnson, Palm, Inc., Vodafone, Kronos and Kanexa.
Zacks Analyst Blog Highlights: Quilmes Industrial, AmBev, Merck & Co. and CONMED Corp.
Zacks Analyst Blog Highlights: Radware, Laureate Education and Cerus Corp.
Zacks Analyst Blog Highlights: Pfizer, Procter & Gamble and Dynavax Technologies.
Zacks Analyst Blog Highlights: Motorola, Apple, Abbott Labs, Boston Scientific and Johnson & Johnson.
Zacks Analyst Blog Highlights: CNOOC, Playtex Products, Proctor & Gamble and Johnson & Johnson.
Zacks Analyst Blog Highlights: Abbott Labs, Boston Scientific, Johnson & Johnson, Motorola and Nokia.

Terms of use | Copyright © 2010 Farlex, Inc. | Feedback | For webmasters | Submit articles